Back to search

Article

Immunogenicity and safety of inactivated SARS-CoV-2 vaccine (CoronaVac) using two-dose primary protocol in children and adolescents (Immunita-002, Brazil): A phase IV six-month follow up

2024-02-29

Abstract excerpt

<title>Abstract</title> <p>Introduction: Vaccines are essential for the prevention and control of several diseases, indeed, monitoring the immune response generated by vaccines is crucial. The immune response generated by vaccination against SARS-CoV-2 in children and adolescents is not well defined regarding to the intensity and medium to long-term duration of a protective immune response, which may point out t...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
bbfce74a-8fe8-5092-9888-5ab3d71f3fb3
DOI
10.21203/rs.3.rs-3931021/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Immunogenicity and safety of inactivated SARS-CoV-2 vaccine (CoronaVac) using two-dose primary protocol in children and adolescents (Immunita-002, Brazil): A phase IV six-month follow upDOI 10.21203/rs.3.rs-3931021/v1
Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001): A One Year Period Follow Up Phase 4 StudySemantic proximity
Immunogenicity and reactogenicity of SARS-CoV-2 mRNA and inactivated vaccines in healthy adolescentsSemantic proximity
Immunologic response, Efficacy, and Safety of Vaccines Against COVID-19 Infection in Children and Adolescents Aged 2 – 21 years old: A Systematic ReviewSemantic proximity
Immunogenicity Against Wild-Type and Omicron SARS-CoV-2 After a Third Dose of Inactivated COVID-19 Vaccine in Healthy AdolescentsSemantic proximity
An Evaluation of the Safety and Immunogenicity of MVC-COV1901: Results of an interim analysis of a phase III, parallel group, randomized, double-blind, active-controlled studySemantic proximity
Analysis of immunization time, amplitude, and adverse events of seven different vaccines against SARS-CoV-2 across four different countriesSemantic proximity
Efficacy and Safety of a COVID-19 Inactivated Vaccine in Healthcare Professionals in Brazil: The PROFISCOV StudySemantic proximity
Humoral and cellular immune responses to CoronaVac assessed up to one year after vaccinationSemantic proximity
Humoral and Cellular Immune Responses of COVID-19 vaccines against SARS-Cov-2 Omicron variant: a systemic reviewSemantic proximity
Differential immune response induced by two immunization schedules with an inactivated SARS-CoV-2 vaccine in a randomized phase 3 clinical trialSemantic proximity
Immunogenicity and Safety of Gamma, Omicron BA.4/5 and Bivalent SARS-CoV-2 RBD-based Protein Booster Vaccines in Adults Previously Immunized with Different Vaccine Platforms: a Phase II/III, Randomized, Clinical TrialSemantic proximity
Efficacy of Heterologous Boosting Using Recombinant SARS-CoV-2 Fusion Protein Vaccine: A Randomized, Double-Blind and Placebo-Controlled Phase III TrialSemantic proximity
Select a neighboring publication to make it the new centre.